{"schema_version":"secwatch.filing_event.v1","accession":"0001680367-23-000049","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.838026+00:00","generated_at":"2026-06-11T18:07:27.277535+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Shattuck Labs Q2 net loss $21.3M ($0.50/sh); cash $117.2M; SL-172154 trials advancing","bullets":["Cash and investments $117.2M at June 30, 2023, down from $214.2M a year earlier; runway through end of 2024.","Net loss of $21.3M ($0.50 per share) for Q2 2023 vs. $27.4M ($0.65) in Q2 2022; R&D spend decreased to $18.2M.","Phase 1A PROC monotherapy data presented at ASCO 2023; 3 mg/kg dose selected for combination cohorts.","Enrollment completed in dose-escalation part of Phase 1A/B for SL-172154 in AML/HR-MDS; initial combo data expected Q4 2023.","GADLEN platform: second NHP toxicology study showed inferior B-cell depletion; no IND planned until resolved."],"urls":{"canonical":"https://secwatch.observer/filing/0001680367-23-000049","json":"https://secwatch.observer/filing/0001680367-23-000049.json","markdown":"https://secwatch.observer/filing/0001680367-23-000049.md","text":"https://secwatch.observer/filing/0001680367-23-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000168036723000049/0001680367-23-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000168036723000049/sttk-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:07:27.277535+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"093c9c436309a2fef4fb6ff0b439d0e0bbcc9873","claim":"Shattuck Labs, Inc. reported financial results for quarter ended June 30, 2023.","evidence_excerpt":"On August 10, 2023, Shattuck Labs, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680367/000168036723000049/0001680367-23-000049-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}